ANAPTYSBIO, INC — Director's Dealing 2018

Dec 19, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANAPTYSBIO INC (ANAB)
CIK: 0001370053
Period of Report: 2018-12-17

Reporting Person: Londei Marco (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-12-17	Common Stock	M	8048	$0.70	Acquired	152925	Direct
2018-12-17	Common Stock	M	22000	$6.93	Acquired	174925	Direct
2018-12-17	Common Stock	S	12120	$65.3612	Disposed	162805	Direct
2018-12-17	Common Stock	S	3185	$66.3787	Disposed	159620	Direct
2018-12-17	Common Stock	S	8002	$67.5686	Disposed	151618	Direct
2018-12-17	Common Stock	S	6741	$68.4732	Disposed	144877	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-12-17	Employee Stock Option (Right to Buy)	$0.70	M	8048	Disposed	2024-10-27	Common Stock (8048)	Direct
2018-12-17	Employee Stock Option (Right to Buy)	$6.93	M	22000	Disposed	2025-08-13	Common Stock (22000)	Direct

Footnotes

F1: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.

F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.00 to $65.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.00 to $66.92 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.02 to $68.01 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.05 to $68.73 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6: The stock option vested and became exercisable as to 25% of the shares subject to the option on October 24, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

F7: The stock option vested and became exercisable as to 25% of the shares subject to the option on August 13, 2016, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

F8: In addition to the remaining options to purchase 80,283 shares of common stock as set forth in Table II, the Reporting Person also holds (i) 144,877 shares of common stock held directly; and (ii) additional options to purchase up to an aggregate of 138,000 shares of common stock, which options vest according to their terms.